Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410577 · ClinicalTrials.gov registry record · NA
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02410577: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02410577 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410577, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
Primary Outcome
This will be measured by J591 uptake in PET scan.
Interventions
- OTHER Blood draw
- DEVICE PET/CT Scan
- DEVICE MRI
- DRUG 89Zr-J591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-08 |
| Phase | NA |
What the finished NCT02410577 record still lists
NCT02410577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT02410577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02410577 about?
NCT02410577 is a clinical study titled "89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme". The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
What is the current status of trial NCT02410577?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-04. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02410577?
The interventions under investigation include: Blood draw (OTHER), PET/CT Scan (DEVICE), MRI (DEVICE), 89Zr-J591 (DRUG).
Who is sponsoring clinical trial NCT02410577?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02410577's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia